ITGAM and myelodysplastic syndrome: To investigate whether the synergistic activity of decitabine plus olaparib did also impact on myeloid differentiation, we evaluated by FACS analysis the percentage of CD117+/CD123+ hematopoietic progenitors and CD11b+/CD16+ neutrophils in four MDS samples, untreated or treated with the indicated concentrations of the drugs.